Clinical Trial Update: Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

This is a completed Phase 2 clinical trial evaluating bevacizumab in combination with tocotrienol for recurrent ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Tocotrienol (tocotrienol (vitamin E) supplement)

Snippet

Sponsor: Vejle Hospital | Conditions: Ovarian Cancer Recurrent | Phase 2 | Status: COMPLETED